Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy

被引：0
作者：
Nermine H. Zakaria
Doaa Hashad
Marwa H. Saied
Neamat Hegazy
Alyaa Elkayal
Eman Tayae
机构：
[1] University of Alexandria,Department of Clinical and Chemical Pathology, Faculty of Medicine
[2] University of Alexandria,Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine
来源：
Human Genomics | / 17卷
关键词：
HER2-positive breast cancer; Genetic variants; NGS; Trastuzumab; Drug resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer
    Hudis, CA
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (01): : 12 - 13
  • [32] Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer
    Sanford, Mark
    TARGETED ONCOLOGY, 2014, 9 (01) : 85 - 94
  • [33] Trastuzumab emtansine: a game changer in HER2-positive early breast cancer
    Mano, Max S.
    FUTURE ONCOLOGY, 2020, 16 (32) : 2595 - 2609
  • [34] Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
    Ami Hori
    Masafumi Shimoda
    Yasuto Naoi
    Naofumi Kagara
    Tomonori Tanei
    Tomohiro Miyake
    Kenzo Shimazu
    Seung Jin Kim
    Shinzaburo Noguchi
    Breast Cancer Research, 21
  • [35] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [36] Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
    Hori, Ami
    Shimoda, Masafumi
    Naoi, Yasuto
    Kagara, Naofumi
    Tanei, Tomonori
    Miyake, Tomohiro
    Shimazu, Kenzo
    Kim, Seung Jin
    Noguchi, Shinzaburo
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [37] HER2-Positive early breast cancer and trastuzumab: A surgeon's perspective
    Kulkarni, Swati
    Hicks, David G.
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (06) : 1677 - 1688
  • [38] Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
    Jeyakumar, Alwin
    Younis, Tallal
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [39] A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer
    Dent, S.
    Ammendolea, C.
    Christofides, A.
    Edwards, S.
    Incekol, D.
    Pourmirza, B.
    Kfoury, S.
    Poirier, B.
    CURRENT ONCOLOGY, 2019, 26 (01) : E70 - E80
  • [40] Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
    Henry G. Kaplan
    Judith A. Malmgren
    Boya Guo
    Mary K. Atwood
    Breast Cancer Research and Treatment, 2022, 195 : 171 - 180
12345